Posts tagged tablet
IntelGenx initiates Phase 2a Montelukast VersaFilm trial in AD

IntelGenx (OTCQX:IGXT; TSXV:IGX) has initiated the Phase 2a proof-of- concept clinical trial with its Montelukast VersaFilm in Alzheimer’s disease patients, following clearance by Health Canada. 

Read More
Tetra Bio-Pharma updates Dronabinol XL AdVersa development plans

Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) is partnering with a major manufacturer of controlled active pharmaceutical ingredients in the U.S. to  manufacture Dronabinol XL AdVersa as part of the company’s plans to submit a 505(b)(2) NDA for the treatment of chemotherapy-induced nausea and vomiting and anorexia associated with weight loss in patients with AIDS.

Read More
IntelGenx, Tetra in development term sheet

IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol.

Read More
Opioid addiction treatment continues to grab headlines

An article in the latest issue of Guernica, a magazine of art and politics, details the plight of doctors prescribing buprenorphine, a medication for the treatment of opiate addiction.

Unlike methadone, buprenorphine was approved for use in a general office setting. A doctor can apply to get a waiver to prescribe buprenorphine and treat someone suffering with addiction. However, there are severe restrictions on the availability of the medication.

Read More
HHS ups buprenorphine prescribing to treat opioid addiction

In a speech today, President Obama announced that the Department of Health and Human Services (HHS) has issued a new proposed rule to increase the current patient limit for qualified physicians who prescribe buprenorphine to treat opioid addiction.

The proposed rule will increase the patient limit to 200 patients from 100 for physicians who have been trained and waivered for more than a year to prescribe buprenorphine.

Read More